Chapter 3

Ownership and Incentives

The value case for Vital Farms rests on a margin and EBITDA recovery by fiscal 2027. The people who have to deliver it are paid, and part-own the company, in ways that line up with that outcome — but the founder has been stepping back. Matt O'Hayer trimmed his stake from 27.4% at the 2021 IPO to 16.3% and retired from the board in February 2026 [1]. Against that, the FY2025 long-term equity grant vests only on FY2027 net-revenue and EBITDA-margin targets, and nearly the whole board bought stock in the open market as the price fell.

The founder steps back, but stays the largest owner

Matthew O'Hayer founded Vital Farms in 2007 with, by the company's telling, twenty hens, and pioneered the pasture-raised category [2]. In February 2026 he retired as Executive Chairperson and left the board, converting to a non-employee advisory role under a March 2026 resignation agreement for which he received no compensation in FY2025 [3]. His reported beneficial ownership has declined steadily across successive Schedule 13G/A filings — from 27.4% in 2021 to 16.05% by November 2025 — and stood at 16.3%, or 7,024,402 shares, in the April 2026 proxy [4].

Source: SEC Schedule 13G/A filings 2021–Nov 2025, as reported; April 2026 figure per the 2026 Proxy Statement [5].

Two readings sit inside that line. The bearish one: a founder who cut his holding by roughly eleven percentage points and left the board in the same window the avian-flu price-gap windfall began to unwind. The offsetting facts are that the sell-down was gradual and spread over five years — most of it well before the 2026 collapse — and that at 16.3% he remains, by a wide margin, the largest single holder, ahead of BlackRock at 12.6% and Vanguard at 6.5% [6]. A retiring 68-year-old founder diversifying a concentrated position is ordinary; the fact worth watching is whether the pace of reduction accelerates now that he no longer sits on the board.

Who runs it now

On O'Hayer's retirement the board elected Russell Diez-Canseco — CEO since 2019 and a company operator since 2014 — to the added role of Executive Chairperson, so the chair and chief-executive titles are now combined in one person [7]. Combining the roles cuts against the board-independence a governance-minded investor prefers, and the board is classified into three staggered classes, a structure that slows any change of control [8]. Both are mitigated rather than absent: seven of the eight directors are independent, with Diez-Canseco the sole non-independent member because of his combined role [9].

The independent bench is well-matched to a packaged-food scale-up. Glenda Flanagan spent nearly three decades as CFO of Whole Foods, and Denny Marie Post, former CEO of Red Robin, serves as Lead Independent Director [10]; William Cyr is CEO of Freshpet [11]; and Kelly Kennedy, the audit chair, was CFO of The Honest Company [12]. This is a board that has run grocery distribution, natural-foods income statements and consumer brands through their own cycles.

What management is paid to do

The compensation design is where alignment with the reset is most concrete. For FY2025 the committee dropped stock options entirely and set executive equity at 50% performance stock units and 50% time-vesting RSUs. The PSUs cliff-vest after a three-year period ending with fiscal 2027 and pay out between 0% and 200% of target based, in equal halves, on fiscal-2027 net revenue and fiscal-2027 Adjusted EBITDA Margin in the company's existing product categories [13]. Those are precisely the two lines the value/value-trap question turns on: whether revenue holds and whether the margin structure rebuilds after the 2026 trough. Management's largest pay component only converts to shares if the recovery the case depends on actually arrives.

The annual cash bonus behaved the same way in FY2025. It was tied 50/50 to net revenue and Adjusted EBITDA and earned at 93% of target — the revenue half paid 84% because actual net revenue of $759.4M fell short of the $784.5M target, while the EBITDA half paid 103% on $114.0M against a $113.4M target [14]. Pay moved down when a goal was missed, which is the point of a formula.

Source: 2026 Proxy Statement, Summary Compensation Table, fiscal year 2025 [15].

The absolute numbers are modest for a company that earned $66M in FY2025. The CEO's total of $3.6M is roughly two-thirds equity and cash-incentive, and it fell from $6.0M in FY2024 — the prior year carried a larger one-time equity grant — so realized pay tracked the softer year [16]. The CEO-to-median-employee pay ratio is 44:1 against a median crew-member wage of $81,259, low for a public company of this profile [17].

The surrounding governance hygiene is clean. The company raised its stock-ownership guidelines in 2025 to five times salary for the CEO, two times for other officers and five times the cash retainer for directors; it has a clawback policy adopted in 2023, prohibits executive hedging, and permits pledging only with board approval, with no shares currently pledged [18]. Shareholders ratified the program with 93.1% support at the first say-on-pay vote in 2025 [19].

Insiders bought the collapse

The clearest signal of conviction is what directors and officers did with their own money during the drawdown. Between March and June 2026 — as the shares fell through the low teens and into single digits — at least a dozen open-market purchases were filed by insiders, and no open-market sales. Nearly the entire independent board participated, along with several operating officers.

Source: SEC Form 4 filings, open-market purchases (transaction code P), March–June 2026, as reported.

The dollar amounts are not large — most directors bought roughly a retainer's worth, $20,000 to $50,000 — so this is a signal of confidence rather than a needle-moving change in ownership. It is worth weighting for two reasons. First, it is broad: it is not one insider but almost the whole board and several officers acting within days of each other. Second, the operating officer closest to the cost structure, Chief Supply Chain Officer Joseph Holland, made the single largest buy, 12,484 shares at $8.00, at a time when the margin recovery was still an open question. The main caveat is that it says nothing new about the founder, who was not among the buyers and continues to hold a diminishing, if still dominant, stake.

What would change the read

The alignment picture is favorable on balance: management's long-term equity is tied to the fiscal-2027 revenue-and-margin recovery, pay flexed down when FY2025 revenue missed, governance controls are in place, and insiders bought the drawdown. The evidence that would revise it is specific and checkable. If O'Hayer's Schedule 13G/A filings show the sell-down accelerating now that he has left the board, that would weaken the founder-conviction leg. If the FY2026 or FY2027 PSU targets are later reset lower — the kind of disclosure that appears in the following year's proxy — the pay-for-recovery link would loosen. And the corporate buyback that ran alongside negative free cash flow (Financials and Estimates) sits in tension with these same insiders spending personal cash on the stock: the first draws the balance-sheet cushion, the second does not.